Skip to main content
. 2021 Jul 5;7(2):e001609. doi: 10.1136/rmdopen-2021-001609

Figure 4.

Figure 4

Predicted median (95% CI) time (days) to pain improvement as a function of baseline pain severity in patients with PsA receiving tofacitinib 5 mg twice daily. Results from the parametric model (final selected model (log-normal distribution) with the smallest AIC). AIC, Akaike information criterion; PsA, psoriatic arthritis.